ABSTRACT

Introduction: Fibromyalgia represents the most prevalent of the group of conditions that are known as central sensitivity syndromes. Approximately 2–5% of the adult population in the United States is affected by Fibromyalgia. This pain amplification syndrome has an enormous economic impact as measured by work absenteeism, decreased work productivity, disability and injury compensation, and over-utilization of healthcare resources. Multiple studies have shown that early diagnosis of this condition can improve patient outlook, and redirect valuable health care resources toward more appropriate targeted therapy. Efforts have been made toward improving diagnostic accuracy through updated criteria.

Areas Covered: Reviewed here are 1) reasons for the need for more accurate diagnosis of Fibromyalgia, (2) a review of the evolution of Fibromyalgia to current times, and (3) the proliferation of currently available diagnostic criteria and problems related to each of them. From initial literature review until October 2020, PubMed, Embase, and Scopus were searched for applicable literature.

Expert Opinion: A discussion of ongoing efforts to obtain a biomarker to enhance diagnostic accuracy concludes this review. A need to include rheumatologists as part of the care team of patients with Fibromyalgia is emphasized.

摘要

简介： 纤维肌痛代表了被称为中枢敏感性综合征的一组病症中最普遍的一种。在美国，大约 2-5% 的成年人受到纤维肌痛的影响。这种疼痛放大综合症具有巨大的经济影响，表现为旷工、工作效率下降、残疾和伤害补偿以及医疗资源的过度利用。多项研究表明，这种疾病的早期诊断可以改善患者的前景，并将宝贵的医疗资源重新导向更合适的靶向治疗。已通过更新标准努力提高诊断准确性。

涵盖的领域：此处审查了 1) 需要更准确地诊断纤维肌痛的原因，(2) 审查纤维肌痛到现在的演变，以及 (3) 当前可用的诊断标准的扩散以及与每个相关的问题他们。从最初的文献综述到 2020 年 10 月，在 PubMed、Embase 和 Scopus 中搜索了适用的文献。

专家意见：本综述总结了为获得生物标志物以提高诊断准确性而正在进行的努力的讨论。强调需要将风湿病学家作为纤维肌痛患者护理团队的一部分。